Empowered Funds LLC Has $1.94 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Empowered Funds LLC increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 315.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,064 shares of the biopharmaceutical company’s stock after acquiring an additional 5,362 shares during the period. Empowered Funds LLC’s holdings in Alnylam Pharmaceuticals were worth $1,943,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ALNY. Huntington National Bank boosted its position in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $26,000. Washington Trust Advisors Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $42,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 6.2 %

Shares of ALNY opened at $248.79 on Thursday. The company’s 50-day moving average price is $273.83 and its 200 day moving average price is $236.76. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market cap of $32.09 billion, a P/E ratio of -94.96 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.15 earnings per share. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Barclays lifted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $198.00 to $370.00 in a report on Friday, August 16th. Bank of America increased their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.